Technical Analysis for SRNEQ - Sorrento Therapeutics Inc

Grade Last Price % Change Price Change
A 0.3380 -3.43% -0.0120
SRNEQ closed up 15.51 percent on Friday, March 17, 2023, on 1.91 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup -3.43%
Pocket Pivot Bullish Swing Setup -3.43%
Outside Day Range Expansion -3.43%
NR7 Range Contraction 11.55%
Narrow Range Bar Range Contraction 11.55%
Inside Day Range Contraction 11.55%
Gapped Up Strength 9.03%
Hot IPO Pullback Bullish Swing Setup 9.14%
Down 3 Days in a Row Weakness 9.14%
Gapped Down Weakness 9.14%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Gapped Up (Partial) about 1 hour ago
Down 3% about 1 hour ago
Up 5% about 1 hour ago
Up 3% about 1 hour ago
Down 1% about 1 hour ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Sorrento Therapeutics Inc Description

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc.


Keywords: Medicine Biotechnology Medical Specialties Cancer Biopharmaceutical Life Sciences Immunology Immune System Cell Therapy Osteoarthritis Infection Monoclonal Antibodies Melanoma Fibromyalgia Multiple Myeloma Neurodegenerative Diseases Antibody Chimeric Antigen Receptor T Cell Inflammatory Therapies For Cancer Back Pain Monoclonal Antibody Therapy Drug Delivery Technology Host Disease Amyloidosis Co V 2 Ipilimumab Late Stage Cancer Lidocaine Mayo Clinic

Is SRNEQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 0.3949
52 Week Low 0.25
Average Volume 5,521,831
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.3285
Average True Range 0.0557
RSI 68.05
ADX 0.0
+DI 14.2307
-DI 10.2528
Chandelier Exit (Long, 3 ATRs) 0.2278
Chandelier Exit (Short, 3 ATRs) 0.4171
Upper Bollinger Bands 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0006
MACD Signal Line -0.0006
MACD Histogram 0.0012
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.5000
Resistance 3 (R3) 0.4967 0.4433 0.4750
Resistance 2 (R2) 0.4433 0.4051 0.4450 0.4667
Resistance 1 (R1) 0.3967 0.3815 0.4200 0.4000 0.4583
Pivot Point 0.3433 0.3433 0.3550 0.3450 0.3433
Support 1 (S1) 0.2967 0.3051 0.3200 0.3000 0.2417
Support 2 (S2) 0.2433 0.2815 0.2450 0.2333
Support 3 (S3) 0.1967 0.2433 0.2250
Support 4 (S4) 0.2000